ENZYMINHIBITOREN

European patent · EP1963315 · In force

Register entry

Publication number
EP1963315
Application number
EP06820620
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 21, 2006
Published
Sep 3, 2008
Granted
Oct 8, 2014
Protection ends at the latest
Dec 20, 2026
Next annual fee due
Dec 31, 2026
IPC classes
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 37/08 (2006.01)
Priority
GB 0526169 22.12.2005
GB 0620884 20.10.2006
PCT application
PCT/GB2006/004854 21.12.2006
PCT publication
WO2007/072017 28.06.2007
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  5. Apr 4, 2020

    Transferred

    Owner
    Cancer Research Technology Limited, Angel Building, 407 St John Street, London, EC1V 4AD, United Kingdom → The Institute of Cancer Research: Royal Cancer, Hospital, 123 Old Brompton Road, London SW7 3RP, United Kingdom

    Published in Swissreg on 04.04.2020

  6. Feb 7, 2015

    Agent entered

    Representative
    MICHELI & CIE SA, 122, Rue de Genève, Case postale 61, 1226 Thônex

    Published in Swissreg on 07.02.2015

  7. Oct 8, 2014

    Granted

    Published in Swissreg on 08.10.2014

Parties

Inventor

BAVETSIAS, Vassilios

Sutton, Surrey SM2 5NG, GB

MACDONALD, Edward

Sutton, Surrey SM2 5NG, GB

LINARDOPOULOS, Spyridon

Sutton, Surrey SM2 5NG, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.